Navigation Links
First Artificial Heart patient has Major setback

The first recipient of a self-contained artificial heart suffered bleeding in his brain in the same area damaged by a stroke 10 days ago. The latest setback caused swelling and made the patient, Robert Tools, 59, of Franklin, Kentucky, less responsive, implant surgeon Laman Gray said. //

Robert Tools received the AbioCor mechanical heart on July 2 at Jewish Hospital in Louisville. At the time, he was so ill he had been given little chance of living more than 30 days without it. Tools improved after the implant and had even been able to dine out at restaurants and go fishing. Last month, doctors were hoping he would be able to go home for Christmas.

But the stroke November 11 left Tools partially paralyzed on his right side and unable to speak. He has been on a ventilator to help him breathe. Tools also suffered gastrointestinal bleeding again last week. Similar bleeding during the first two months after the heart implant kept doctors from giving Tools blood-thinning anticoagulants that reduce the risk of clots, which can cause strokes.

Doctors finally were able to give Tools anti-coagulant medicine during the last month, and that could have had the unintended effect of freeing the already-formed clot, probably not much larger than a pinhead, and allowing it to move to the brain.


'"/>




Page: 1

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First head-to-head trials of once weekly Fosamax and Actonel therapies
5. WHO Declares Vietnam First Country to Control SARS
6. Russia Reports First SARS Case
7. Hope for First New Melanoma Treatment in Decades
8. First global SARS meet opens
9. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
10. Hyderabad To Have Asia’s First Catheter Making Uni
11. First telesurgery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: